Research Papers:

Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia

Gaozhen Jia, Zhenyang Dong, Chenxia Sun, Fuping Wen, Haifeng Wang, Huaizu Guo, Xu Gao, Chuanliang Xu, Chenghua Yang and Yinghao Sun _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:76987-76999. https://doi.org/10.18632/oncotarget.20299

Metrics: PDF 1538 views  |   HTML 3344 views  |   ?  


Gaozhen Jia1,*, Zhenyang Dong1,*, Chenxia Sun3, Fuping Wen3, Haifeng Wang1, Huaizu Guo4, Xu Gao1, Chuanliang Xu1, Chenghua Yang2,3 and Yinghao Sun1

1Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 2000433, China

2Joint Center for Translational Research of Chronic Diseases, Changhai Hospital, Second Military Medical University, Shanghai 2000433, China

3Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China

4State Key Laboratory of Antibody Medicine and Targeted Therapy, Shanghai 201203, China

*These authors have contributed equally to this work

Correspondence to:

Yinghao Sun, email: [email protected]

Chenghua Yang, email: [email protected]

Keywords: prostate cancer, PSA, glycosylation, benign prostate hyperplasia, EPS-urine

Received: February 09, 2017    Accepted: June 27, 2017    Published: August 16, 2017


The prostate specific antigen (PSA) test is widely used for early diagnosis of prostate cancer (PCa). However, its limited sensitivity has led to over-diagnosis and over-treatment of PCa. Glycosylation alteration is a common phenomenon in cancer development. Different PSA glycan subforms have been proposed as diagnostic markers to better differentiate PCa from benign prostate hyperplasia (BPH). In this study, we purified PSA from expressed prostate secretions (EPS)-urine samples from 32 BPH and 30 PCa patients and provided detailed PSA glycan profiles in Chinese population. We found that most of the PSA glycans from EPS-urine were complex type biantennary glycans. We observed two major patterns in PSA glycan profiles. Overall there was no distinct separation of PSA glycan profiles between BPH and PCa patients. However, we detected a significant increase of glycan FA2 and FM5A2G2S1 in PCa when compared with BPH patients. Furthermore, we observed that the composition of FA2 glycan increased significantly in advanced PCa with Gleason score ≥8, which potentially could be translated to clinic as a marker for aggressive PCa.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20299